Lurbinectedin is a medication used to treat certain types of cancer, including small cell lung cancer. It is important to know whether or not this medication is covered by insurance.

According to the drug patent watch website [1], the patent for lurbinectedin was granted in 2016 and is set to expire in 2036. However, the website does not provide any information on insurance coverage for this medication.

The Zepzelca website [2] provides a FAQ section that includes information on insurance coverage. According to the website, Zepzelca is covered by most insurance plans, including Medicare and Medicaid. However, the website does not specifically mention lurbinectedin.

The Cigna website [3] provides information on lurbinectedin, including its uses, dosages, and potential side effects. The website also includes information on insurance coverage for this medication. According to the website, lurbinectedin may be covered by insurance, but coverage may vary depending on the specific insurance plan. Patients are advised to check with their insurance provider to determine if lurbinectedin is covered under their plan.

In conclusion, while the sources do not provide a clear answer on whether lurbinectedin is covered by insurance, it is suggested that patients check with their insurance provider to determine coverage.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.zepzelca.com/faq/
[3] https://www.cigna.com/knowledge-center/hw/medications/lurbinectedin-d09579a1.html